Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2).
Diwakar DavarLudimila CavalcanteNehal J LakhaniJustin C MoserMichael MillwardMeredith McKeanMark VoskoboynikRachel E SanbornJaspreet S GrewalAjita NarayanAmita PatnaikJustin F GainorMario SznolAmanda EnstromLori BlanchfieldHeidi LeBlancHeather ThomasMichael J ChisamoreStanford L PengAllison NaumovskiPublished in: Journal for immunotherapy of cancer (2024)
NEON-1 (NCT04186637) and NEON-2 (NCT04920383).